Cancer immunotherapy is entering a new phase—one that extends beyond targeting individual tumour cells and towards...
As biologics and cell and gene therapies continue to advance, manufacturing infrastructure is emerging as a critical det...
As cell and gene therapies move from clinical promise to commercial reality, the industry is increasingly recognising th...
Cell and gene therapies have transformed the treatment landscape for complex diseases, yet scaling these innovations bey...
Researchers at the University of Otago, New Zealand are investigating a blood-based prostate cancer detection approach u...
Sonire Therapeutics has received approximately $13 million in non-dilutive funding through Japan’s NEDO Deep-Tech ...
South Korea-based LG AI Research has signed a master agreement with D&D Pharmatech for a joint next-generation oral ...
Niowave and Ratio Therapeutics have signed a supply agreement for Actinium-225, strengthening Ratio’s access to a ...
Hillhurst Bio has dosed the first subject in its Phase 2a clinical trial evaluating HBI-002 for the treatment of Parkins...
CARsgen Therapeutics has presented new clinical data for two allogeneic CAR-T cell therapy candidates, CT0596 and CT1190...
Rznomics has presented interim Phase 1/2a clinical data for RZ-001, its RNA editing-based anticancer gene therapy for re...
Inflammatory bowel disease is becoming a growing focus within immunology innovation across Asia-Pacific, as the region s...
MaaT Pharma has presented final Phase 3 data from the ARES pivotal trial evaluating MaaT013 in acute graft-versus-host d...
Pfizer has received US FDA approval for an expanded indication of Hympavzi for hemophilia A or B, broadening its use to ...
Eli Lilly has reported detailed Phase III results from three ACHIEVE trials evaluating Foundayo, or orforglipron, an ora...
VERTANICAL has received marketing authorisation in Germany for Exilby, or VER-01, for the treatment of chronic low back ...
The Department of Orthopaedic Surgery at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medi...
Researchers from the National Institute of Education, Nanyang Technological University, Singapore (NIE NTU, Singapore)...
Johnson & Johnson has received US FDA approval for a supplemental Biologics License Application to include evidence ...
An international research team led by the A*STAR Genome Institute of Singapore (A*STAR GIS) has developed HERRO, an arti...
This year’s meeting highlighted a dramatic shift in the geography of cancer drug development. Long viewed as &ldqu...
A study led by Dr Jason Pitt, Principal Investigator at the Cancer Science Institute of Singapore (CSI Si...
As Asia’s biologics ecosystem continues to scale rapidly across monoclonal antibodies, biosimilars, and ad...
The Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) has announced a research partnershi...
Scientists from A*STAR Infectious Diseases Labs (A*STAR IDL), Nanyang Technological University, Singapore’s Lee Ko...
